OBJECTIVE: To assess pharmacokinetics, safety and efficacy of darunavir/ritonavir (DRV/r) and optimized background regimen in treatment-experienced patients (6-17 years). DESIGN: Forty-eight-week, open-label, two-part, phase II study. METHODS: In part I, 44 patients were randomized (1: 1 ratio) to receive a body weight-adjusted, adult-equivalent dose (group A) or a 20-33% higher DRV/r twice daily (b.i.d.) dose (group B). Pharmacokinetics, safety and efficacy were assessed following 2-week dosing (part I), which determined dosing for part II (evaluated 48-week safety and efficacy). RESULTS: In part I, both groups met the protocol-specified criteria for pharmacokinetics and showed favorable tolerability and efficacy. The following body-weight doses were selected: DRV/r 375/50 mg b.i.d. (20-<30 kg), 450/60 mg b.i.d. (30-<40 kg) and 600/100 mg b.i.d. (> or =40 kg); these gave an AUC24h, C0h and Cmax of 102, 114 and 112%, respectively, versus the corresponding mean adult pharmacokinetic parameter. In part II, 80 patients received DRV/r (median age: 14 years, mean baseline HIV-1 RNA: 4.64 log(10)copies/ml). One patient (1%) discontinued (treatment-unrelated grade 3 anxiety). An abnormal mean baseline triglyceride level was normalized at 48 weeks (P < 0.01). At week 48, 65% had at least 1.0 log(10)HIV-1 RNA reduction; 59 and 48% achieved HIV-1 RNA less than 400 and less than 50 copies/ml, respectively (time-to-loss-of-virologic response). Mean age-adjusted weight z-score increased by 0.2 (P = 0.003). CONCLUSION: In treatment-experienced children and adolescents, DRV/r showed comparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved body weight and significant virologic response. DRV/r is a valuable therapeutic option for this population.
RCT Entities:
OBJECTIVE: To assess pharmacokinetics, safety and efficacy of darunavir/ritonavir (DRV/r) and optimized background regimen in treatment-experienced patients (6-17 years). DESIGN: Forty-eight-week, open-label, two-part, phase II study. METHODS: In part I, 44 patients were randomized (1: 1 ratio) to receive a body weight-adjusted, adult-equivalent dose (group A) or a 20-33% higher DRV/r twice daily (b.i.d.) dose (group B). Pharmacokinetics, safety and efficacy were assessed following 2-week dosing (part I), which determined dosing for part II (evaluated 48-week safety and efficacy). RESULTS: In part I, both groups met the protocol-specified criteria for pharmacokinetics and showed favorable tolerability and efficacy. The following body-weight doses were selected: DRV/r 375/50 mg b.i.d. (20-<30 kg), 450/60 mg b.i.d. (30-<40 kg) and 600/100 mg b.i.d. (> or =40 kg); these gave an AUC24h, C0h and Cmax of 102, 114 and 112%, respectively, versus the corresponding mean adult pharmacokinetic parameter. In part II, 80 patients received DRV/r (median age: 14 years, mean baseline HIV-1 RNA: 4.64 log(10)copies/ml). One patient (1%) discontinued (treatment-unrelated grade 3 anxiety). An abnormal mean baseline triglyceride level was normalized at 48 weeks (P < 0.01). At week 48, 65% had at least 1.0 log(10)HIV-1 RNA reduction; 59 and 48% achieved HIV-1 RNA less than 400 and less than 50 copies/ml, respectively (time-to-loss-of-virologic response). Mean age-adjusted weight z-score increased by 0.2 (P = 0.003). CONCLUSION: In treatment-experienced children and adolescents, DRV/r showed comparable exposure to adults with appropriate dose selection, favorable safety and tolerability, improved body weight and significant virologic response. DRV/r is a valuable therapeutic option for this population.
Authors: Tim R Cressey; Ram Yogev; Andrew Wiznia; Rohan Hazra; Patrick Jean-Philippe; Bobbie Graham; Amy Gonzalez; Paula Britto; Vincent J Carey; Courtney V Fletcher; Edward P Acosta Journal: J Pediatric Infect Dis Soc Date: 2017-09-01 Impact factor: 3.164
Authors: Richard M Rutstein; Pearl Samson; Terry Fenton; Courtney V Fletcher; Jennifer J Kiser; Lynne M Mofenson; Elizabeth Smith; Bobbie Graham; Marina Mathew; Grace Aldrovani Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Gloria Huerta-García; José G Vazquez-Rosales; José A Mata-Marín; Leoncio Peregrino-Bejarano; Eric Flores-Ruiz; Fortino Solórzano-Santos Journal: Pediatr Res Date: 2016-03-21 Impact factor: 3.756
Authors: J Jao; W Yu; K Patel; T L Miller; B Karalius; M E Geffner; L A DiMeglio; A Mirza; J S Chen; M Silio; E J McFarland; R B Van Dyke; D Jacobson Journal: HIV Med Date: 2017-11-21 Impact factor: 3.180
Authors: Sharon Nachman; Nan Zheng; Edward P Acosta; Hedy Teppler; Brenda Homony; Bobbie Graham; Terence Fenton; Xia Xu; Larissa Wenning; Stephen A Spector; Lisa M Frenkel; Carmelita Alvero; Carol Worrell; Edward Handelsman; Andrew Wiznia Journal: Clin Infect Dis Date: 2013-10-21 Impact factor: 9.079